GET TO KNOW US BETTER
Who We Are
HE.CA.GEN. is a newly formed, innovative pharmaceutical company based in Northern Greece.
The company brings together a dynamic team of passionate and accomplished entrepreneurs, legal experts, experienced chemical engineers, and master agronomists, specializing in cultivating and processing high-quality pharmaceutical cannabis strains.
This powerful synergy positions HE.CA.GEN. at the forefront of groundbreaking advancements in the pharmaceutical cannabis industry.
GET TO KNOW US BETTER
What We Do
Harnessing the power of natural sunlight, HE.CA.GEN. champions sustainable, high-purity non-irradiated pharmaceutical cannabis production through a state-of-the-art, fully controlled, and automated glasshouse hydroponics cultivation system.
This innovative approach meticulously replicates optimal indoor growing conditions while reducing its environmental footprint.
Our Mission
To create high-quality pharmaceutical cannabis products through innovative and sustainable practices, meeting the industry’s strictest quality standards.
Our commitment to sustainable practices ensures patients receive high purity non-irradiated medicines, fostering improved health and well-being.
Our Vision
To pioneer research and development in the European cannabis market by forging strategic partnerships with research institutes, healthcare academics, and professionals.
Through our focus on R&D, we aim to revolutionize pharmaceutical cannabis and improve patient outcomes.
OUR TEAM
Our team of experts
WHY US
about HE.CA.GEN
Unmatched Expertise
We leverage the combined knowledge of our experienced team to deliver superior cannabis products.
Sustainable Sunlight Optimization
Our state-of-the-art, fully glazed greenhouse with diffused double glazing maximizes natural light diffusion for plant growth while minimizing environmental impact.
Cultivation
Our sterile hydroponics system in a totally enclosed smart greenhouse minimizes environmental impact while replicating ideal indoor growing conditions.
Precision Yields
Through crop steering practices, we achieve optimal harvests and consistent quality.
Pure, High-Quality Products
We produce non-irradiated end flos products with exceptional purity.
Minimally Processed Extracts
We minimize the use of chemical solvents in our extraction process to preserve the natural qualities of the plant material.
Pioneering Techniques
We develop novel pharmaceutical products through solventless cold extraction methods and ongoing research.
Continuous Improvement
Our relentless R&D focuses on optimizing cultivation methods, processing techniques, and future clinical trials to ensure we deliver the best possible products.
WHY US
market overview
Free Markets
These are medical cannabis markets open to free market competition.
Pilot Programs
These are countries which have national medical cannabis pilot programs, which run until a specified end date, beyond which, it is likely medical cannabis access will be widened (if the trial program is not extended). Products used in these programs require approval from health authorities, which makes market entry difficult.
Tightly Controlled Markets
These are medical cannabis markets which are under tight governmental control. This can take the form of product approval requirements, tenders for supply, government-control distribution, etc.
Exceptional Access Markets
These are markets where medical cannabis is only accessed under exceptional circumstances. Patients are given authorization on an individual basis, and products are imported in extremely low quantities on their behalf.
Early/Slow Markets
These are markets where medical cannabis treatment is legal, but patient numbers are extremely low due to lack of developed infrastructure for treatment – e.g., lack of prescribing doctors, restrictive conditions for prescribing, incomplete regulatory framework for medical cannabis treatment, lack of available products, lack of awareness of structures and process for medical cannabis treatment.
Markets in Transition
These are markets where the regulations around medical cannabis treatment have recently changed significantly, so the market is undergoing a transition.
